Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Vladonix6 residuesAEDLVGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: A-6, Peptide Complex A-6, Thymus Bioregulator A-6
In one open-label study of 42 patients, 78% saw their T-lymphocyte parameters return to normal after a single 30-day course. Vladonix is an oral thymus peptide bioregulator from the Khavinson line, containing peptide complex A-6 extracted from calf thymus tissue. The catch: zero PubMed-indexed studies exist under its own name, and the strongest longevity data [1] actually used injectable Thymalin plus Epithalamin. Community adoption is small but consistent, centered on users running 30-day oral courses two to three times per year for age-related immune support. No injections. No reconstitution. Just capsules with meals.
Seventy-eight percent of patients with impaired immunity had their T-lymphocyte counts normalize after 30 days of capsules. That single data point is the core of what Vladonix (peptide complex A-6, oral thymus bioregulator) has going for it. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Vladonix contains a mixture of low-molecular-weight peptides (under 10 kDa) extracted from the thymus glands of young calves. The peptides are short enough, two to four amino acids, that Khavinson's group argues they survive gastric digestion and get absorbed via peptide transporters in the gut. No independent pharmacokinetic study has confirmed that claim for Vladonix specifically. The proposed mechanism is epigenetic. Short-chain peptides from the A-6 complex bind DNA promoter regions in thymic epithelial cells, modulating gene expression tied to T-cell differentiation. In the n=42 study (ages 34 to 65), CD3+ and CD4+ counts increased reliably, and the CD4+/CD8+ ratio returned to normal ranges. B-cell parameters changed less. Here is the honest assessment: zero PubMed results exist for "vladonix" as of 2026. All clinical data comes from one research group. The landmark longevity study (n=266)[1] used injectable Thymalin plus Epithalamin, not oral Vladonix, so its mortality-reduction findings don't transfer directly. Community adoption sits under five Reddit threads; most users run it inside multi-bioregulator stacks alongside Endoluten and Ventfort rather than as a standalone.
Vladonix delivers a mixture of short thymus-derived peptides (peptide complex A-6) that are proposed to reach target immune cells after oral absorption. The absorption theory rests on molecular size. Peptides of two to four amino acids are small enough to resist complete enzymatic breakdown in the gut and get transported via PEPT and LAT peptide transporters. No bridging pharmacokinetic study has confirmed this for Vladonix specifically. Once absorbed, the peptides are proposed to bind specific DNA sequences in promoter regions of immune-related genes. This interaction occurs in thymic epithelial cells and T-lymphocyte precursors. The net effect, per Khavinson's bioregulation model, is modulation of transcription rather than alteration of the underlying DNA sequence. The downstream biological activity is T-cell focused. The peptide complex activates T-lymphocyte maturation, regulates the balance between CD4+ T-helper and CD8+ T-suppressor cells, and normalizes immunological reactivity. It also promotes regeneration in thymic tissue that has undergone age-related involution. These changes persist beyond the active dosing period, consistent with an epigenetic rather than pharmacokinetic mechanism. This mechanism overlaps with injectable Thymalin (the parent extract) and its synthetic dipeptide derivative Thymogen (L-Glu-L-Trp). Vladonix uses the oral route and contains a broader peptide fraction than either.
A single open-label clinical study (n=42, ages 34–65) reported normalization of impaired immune parameters in 78% of subjects, with reliable increases in CD3+ and CD4+ T-lymphocyte counts and restoration of the CD4+/CD8+ ratio. This study was conducted by Khavinson affiliates and has not been independently replicated. The landmark longevity study [1] used injectable Thymalin, not oral Vladonix, so its mortality-reduction findings cannot be directly attributed to this product. Zero PubMed results for "vladonix" as of 2026. Mechanistic support for oral absorption of ultra-short peptides via PEPT/LAT transporters exists in theory but has not been confirmed by bridging PK studies for Vladonix specifically.
Khavinson-affiliated open-label study, n=42 patients with immune dysfunction (ages 34–65): 78% normalized T-lymphocyte parameters (CD3+, CD4+ counts and CD4+/CD8+ ratio) after a 30-day Vladonix course. No PMID: not indexed in PubMed. Summarized via Antiaging-Systems and Bioregulator Atlas. The nearest indexed landmark is PMID 14523363 (combined Thymalin + Epithalamin, injectable, n=266).
Zero PubMed entries for "vladonix". All primary evidence from one research group (Khavinson Institute, St. Petersburg). No blinding, no randomization, no placebo control in the cited clinical study. Oral bioavailability unconfirmed: gastric peptide degradation not formally characterized for the A-6 complex. Half-life and PK parameters are estimated, not measured. No Western regulatory review. Vladimir Khavinson died in 2024, reducing likelihood of future primary trial data from originating group.
Very niche compound discussed almost exclusively in Khavinson bioregulator communities (ProjectBioHacked, AnabolicMinds bioregulator threads, vendor blogs) rather than general peptide forums. Reddit signal is effectively absent: fewer than 5 dedicated threads identifiable. Users typically run Vladonix as part of a multi-bioregulator stack alongside Endoluten and Ventfort rather than as a standalone. Reported benefits are modest and difficult to attribute: reduced infection frequency and improved energy, typically noticed in the post-course weeks rather than during dosing. Oral format is the primary draw over injectable alternatives.
Both the single clinical study and community reports converge on immune support / T-cell normalization as the primary outcome, and both describe effects that persist well beyond the active dosing period. The gap is one of magnitude and confidence: the clinical study quantifies T-lymphocyte parameter normalization; community experience reports softer endpoints (fewer infections, improved energy). No divergence in mechanism or dosing expectation: mechanistically consistent, just weakly evidenced from both directions.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | 2x Daily |
| Aggressive | 20mg | 2x Daily |
Vladonix is an oral capsule. No vials, no bacteriostatic water, no syringes. Each capsule contains 10 mg of peptide complex A-6 with a total capsule weight around 215 mg including excipients. The standard community protocol is 2 capsules (20 mg) daily with breakfast for 30 days. That burns through 60 capsules per course. A 60-cap pack runs $130 to $156 depending on the distributor. If you're running the upper range of the NPCRIZ protocol (2 caps twice daily, 40 mg/day), you'll need 120 capsules per course. Take capsules with food. GI discomfort in the first few days is the most common complaint, and it almost always traces back to empty-stomach dosing. The thing most beginners miss: you won't feel anything during the 30-day course. Community members consistently report that benefits (fewer colds, improved energy) show up 4 to 12 weeks after stopping. Evaluate a course by what happens in the months following, not during.
Standard bioregulator protocol: 1-2 capsules daily for 30 days, then repeat every 3-6 months. Some protocols use a 10-day intensive course for maintenance. Effects persist well beyond the active dosing period.
The Khavinson bioregulator model proposes that ultra-short peptides bind specific DNA promoter sequences in thymic target tissue (thymic epithelial cells and T-lymphocyte precursors), restoring normal gene expression patterns. Under this model, a 30-day course is sufficient to trigger lasting epigenetic changes: continuous supplementation is neither part of the validated protocol nor theoretically necessary. Cycling is built into the foundational mechanism hypothesis, not derived from receptor desensitization, antibody formation, or hormonal axis suppression concerns. The 3–6 month interval reflects the proposed duration of epigenetic persistence in thymic tissue.
Or use the universal Peptide Calculator for any peptide.
Expected: Gradual immune parameter normalization; clinical study observed T-lymphocyte improvements by day 15–30. Community reports reduced infection frequency in the 1–3 months post-course rather than during active dosing.
Monitor: No mandatory lab monitoring for standard preventive protocol. Optional: CD3+/CD4+/CD8+ lymphocyte panel before and 4–6 weeks after course to assess T-cell normalization: the primary proposed mechanism.
Swallow whole with water. Do not open or crush capsules.
If running the upper protocol range, add a second dose of 1 to 2 capsules with lunch or dinner. Avoid evening dosing if you notice immune stimulation disrupting sleep.
Do not skip days; the proposed mechanism is cumulative epigenetic modulation that requires consistent exposure.
Do not continue indefinitely. The Khavinson protocol is specifically designed as pulsed courses.
Most community members repeat at 3 to 4 months. Some practitioners use a 10-day mini-course (20 capsules at 2 per day) as monthly maintenance between full courses.
Store capsules at room temperature (15 to 25 degrees Celsius) in original packaging, away from moisture and direct sunlight. No refrigeration required.
Optional monitoring: run a lymphocyte subpopulation panel (CD3+, CD4+, CD8+, CD4+/CD8+ ratio) before your first course and 4 to 6 weeks after completing it. Normal CD4+/CD8+ ratio is 1.5 to 2.5 in adults.
Thymalin: 10–30 mg IM/SC daily for 5–10 days per course; total course dose lower than oral Vladonix due to superior bioavailability via injectable route
Thymalin has a stronger evidence base (clinical studies indexed in PubMed: PMID 12577695 and PMID 14523363 involve Thymalin). The injectable route bypasses GI degradation, making oral bioavailability assumptions moot. However, Thymalin is not available as a commercial dietary supplement in US/EU markets: requires import or prescription in applicable jurisdictions. Vladonix oral capsules are the accessible consumer alternative.
Pineal bioregulator (A-8). The landmark PMID 14523363 longevity study used combined thymic + pineal peptide treatment. Khavinson explicitly designated Endoluten + Vladonix as the foundational two-bioregulator longevity pair. Complementary organ targets, immune system vs. circadian/hormonal regulation, with no mechanistic overlap.
Vascular bioregulator (A-3). Part of Khavinson's 'first-class' 6-bioregulator protocol alongside Vladonix. Frequently sold as a bundle by US distributors. Addresses cardiovascular aging while Vladonix targets immune aging: complementary targets.
Brain bioregulator (A-5). Included in Khavinson's 6-bioregulator combined protocol for broad geroprotection. Vladonix handles immune-thymic axis; Cerluten handles neural axis: distinct mechanisms, no overlap. Commonly added when cognitive support is a secondary goal.
Injectable longevity peptide (AEDG tetrapeptide). Often added to Vladonix courses by users focused on longevity. Epithalon targets pineal + telomerase; Vladonix targets thymic T-cell maturation: distinct pathways. Community considers this combination equivalent to the original Thymalin + Epithalamin injectable protocol.
Injectable pharmaceutical-grade version of the same thymus peptide fraction (A-6). Stacking Vladonix (oral A-6) with Thymalin (injectable A-6) creates redundant thymic peptide exposure. Choose one route; do not combine.
Thymulin is an endogenous thymic nonapeptide that also targets T-cell maturation. Mechanistic overlap with Vladonix's T-cell stimulation pathway. No combination study exists; concurrent use may cause excessive immune stimulation without additional benefit.
Both Vladonix and Thymosin Alpha-1 stimulate T-lymphocyte maturation and immune activation. Combining two immune-stimulating thymic agents risks excessive T-cell activation, particularly in individuals with borderline autoimmune conditions. Medical supervision required if combining.
Vladonix stimulates T-cell proliferation and maturation: directly opposing the mechanism of immunosuppressant drugs. Concurrent use could counteract transplant rejection prevention or autoimmune management. Contraindicated in organ transplant recipients.
Do not combinePricing updated 2026-04-09
The most important safety concern with Vladonix is immunostimulation in the wrong patient. Anyone with an active autoimmune condition, anyone taking immunosuppressant medications (tacrolimus, cyclosporine, mycophenolate), and organ transplant recipients should not take this product. T-cell stimulation directly opposes the mechanism of anti-rejection drugs. That interaction is not theoretical; it is pharmacologically predictable. The second concern is the evidence gap. No controlled safety trial has been conducted. The total human safety data comes from one unblinded, unrandomized, open-label study of 42 patients (ages 34 to 65), conducted by the same group that developed the product. In that study, no adverse events were recorded. That is reassuring but far from complete. Reported side effects in clinical use: Published literature: none reported. Zero adverse events in the n=42 clinical study. No toxicity, no allergic reactions, no drug dependence across two decades of clinical observation in Russian practice. Community reports: occasional mild GI discomfort (bloating, mild nausea) in the first one to three days when capsules are taken without food. This resolves by taking Vladonix with a full meal. The 40 mg/day dose (4 capsules per day) is more likely to cause GI adjustment than the standard 20 mg/day. Bovine-derived product warning: Vladonix contains peptides extracted from calf thymus tissue. Individuals with known allergies to bovine-derived biological products should not use it. Prion risk is considered lower than for CNS-derived extracts (such as Cerluten or Cortexin) because thymus tissue carries lower prion burden than neural tissue; however, independent prion testing has not been published for Vladonix. Supply chain risk: legitimate Vladonix is manufactured by NPCRIZ in St. Petersburg. Counterfeit Khavinson bioregulators exist in the market. Batch-to-batch consistency and cold chain integrity cannot be verified from third-party resellers. Pregnancy and breastfeeding: no safety data exists for these populations. Do not use. Children under 18: not studied. Not recommended. When to stop and see a doctor: any sign of allergic reaction (rash, urticaria, difficulty breathing), fever or signs of immune overactivation (unexpected lymphadenopathy, joint pain), or any new autoimmune symptoms.
Verify Vladonix dosing and safety with a second opinion
Bovine thymus tissue-derived polypeptide extract manufactured in Russia under NPCRIZ/Khavinson Institute standards. No Western regulatory equivalent to FDA GMP oversight. No independent third-party purity or potency testing is publicly available. Counterfeit Khavinson bioregulators are documented in the market. Post-2022 Russia sanctions create ongoing logistics and payment disruption for direct orders; reseller supply chain integrity cannot be verified. Oral bioavailability of the peptide complex is unconfirmed by independent PK study.
| Test | When | Target |
|---|---|---|
| Lymphocyte subpopulation panel (CD3+, CD4+, CD8+, CD4+/CD8+ ratio) | Before first course and 4–6 weeks after completing the 30-day course | CD4+/CD8+ ratio: normal adult range 1.5–2.5; CD4+ count: 500–1500 cells/µL (lab-specific norms vary) |
| Natural killer (NK) cell activity | Optional; before first course if immune compromised | — |
The primary proposed mechanism and the endpoint measured in the Khavinson n=42 study. Most direct biomarker to assess T-cell normalization. Useful for tracking response across courses.
Thymic peptides can also influence innate immune components. NK cell activity may provide an additional data point on immune restoration beyond T-cell subpopulation metrics.
Course initiation. No noticeable changes expected. Peptides begin interacting with immune cell gene expression. Establish consistent daily dosing with meals.
Early immune modulation underway. Some users report improved energy and fewer minor symptoms. T-cell precursor differentiation may be accelerating at the cellular level.
Clinical studies showed measurable improvements in CD3+, CD4+ counts and CD4/CD8 ratios by this point. 78% of patients experienced normalized immune parameters. Complete the full 30-day course.
Immune improvements continue to develop after the course ends. Reduced frequency of acute respiratory infections reported in observational data. Benefits persist without continued dosing.
Sustained immune benefits from a single course. Next course typically administered at the 3-6 month mark depending on individual needs and practitioner guidance.
Days 1 to 7: Nothing happens that you can feel. The short-chain peptides from the A-6 complex are proposed to begin interacting with DNA promoter regions in thymic epithelial cells and T-lymphocyte precursors at the molecular level. Occasional mild bloating in the first few days if you skip meals before dosing. Take capsules with food and this resolves. Days 8 to 15: Early immune modulation may be underway at the cellular level. The n=42 clinical study reported measurable CD3+ and CD4+ improvements by mid-course in responsive patients. Some community users note improved energy or a vague sense of improved wellbeing. Most users report nothing specific at this stage. That is normal. Days 16 to 30: This is when the clinical study measured its primary outcomes. T-lymphocyte normalization (CD3+, CD4+, CD4+/CD8+ ratio) appeared by end-of-course in 78% of subjects with immune dysfunction. Finish the full 30 days. Most community users still report minimal subjective effects during active dosing; the benefit is cumulative and shows up later. Weeks 5 to 12 (post-course): The best window for noticing benefits, according to community reports. Reduced frequency of colds and respiratory infections is the most commonly cited outcome. Improved energy levels come second. The proposed explanation is that epigenetic changes in thymic tissue continue to produce downstream T-cell effects after dosing stops. Months 3 to 6: Time to evaluate whether another course is warranted. The NPCRIZ protocol specifies repeat at 3 to 6 month intervals. Most community members who run ongoing protocols repeat at 3 to 4 months. Elderly users focused on geroprotection tend to run two full 30-day courses per year. Some practitioners insert a 10-day mini-course (20 capsules) as monthly maintenance between full courses.
Short-chain peptides from A-6 complex begin interacting with DNA promoter regions in thymic epithelial cells and T-lymphocyte precursors. No measurable immune parameter changes expected in week 1.
No noticeable changes. Standard experience. Occasional mild GI adjustment (bloating) in days 1–3 if taken without food.
T-lymphocyte precursor differentiation and maturation proposed to be underway. The clinical study reported measurable CD3+ and CD4+ improvements by mid-course in responsive patients.
Some users note improved energy or sense of wellbeing. No dramatic changes expected. Most users report nothing specific at this stage.
The Khavinson-affiliated n=42 study found measurable T-lymphocyte normalization (CD3+, CD4+, CD4+/CD8+ ratio) by end of a 30-day course in 78% of subjects with immune dysfunction. Complete the full 30-day course.
Still minimal subjective effects during active dosing for most users. Benefit is cumulative and typically noticed in the weeks after stopping.
The epigenetic mechanism proposed by Khavinson predicts lasting gene expression changes in thymic tissue that persist beyond the active dosing period. Effects should continue to develop 4–8 weeks post-course.
Most commonly cited as the best window for noticing benefits: reduced frequency of colds/respiratory infections, improved energy. Most community members evaluate a course by outcomes in this 6–10 week window.
NPCRIZ protocol specifies repeat at 3–6 month intervals. No comparative data on optimal inter-course interval. Some practitioners use a 10-day mini-course (20 caps) as monthly maintenance between full courses.
Most users repeat at 3–4 months if benefits have faded. Elderly users oriented toward broad geroprotection may run 2 full 30-day courses per year as their primary anti-aging protocol component.
Source: Estimated from general short peptide pharmacokinetics; no Vladonix-specific PK data published. Oral bioregulator peptides are rapidly degraded.
Loading the interactive decay curve.
Vladonix is classified as a dietary supplement in Russia, manufactured by NPCRIZ under the Khavinson Institute of Bioregulation and Gerontology. It is not approved by the FDA, EMA, or any Western regulatory agency. No regulatory application has been filed outside of Russia. In the United States, Vladonix is sold by specialty distributors (Qi Supplements, Vita-Stream, CosmicNootropic, RuPharma) as a research compound or dietary supplement. It is not available through compounding pharmacies or mainstream supplement retailers. Post-2022 sanctions on Russia have created ongoing logistics and payment disruptions for direct orders. Supply chain integrity for international shipments cannot be independently verified. Vladonix is not listed on the WADA prohibited substances list. However, athletes subject to anti-doping testing should verify current status with their governing body before use, as thymic peptide extracts could theoretically trigger scrutiny. This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
